Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Veritone Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Veritone Inc trades at $0.53 (market cap $53.70M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 18.2× Veritone Inc's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Veritone Inc for 13 Days on average.
| MRVI | VERI | |
|---|---|---|
Market Cap | $977.37M | $53.70M |
Volume | 2,742,564 | 4,439,104 |
Sector | Health | Technology |
52-Week High | $9.00 | $8.39 |
52-Week Low | $2.83 | $0.53 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $1.08B | $89.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Veritone (VERI) trades at $0.59, down 2.64% today, with a bearish technical outlook despite oversold RSI readings. The company shows significant financial challenges with a -117.54% net income margin and consistent quarterly losses, though it maintains a reasonable P/S ratio of 0.5. Recent developments include a $15 million equity offering and new partnerships with ATP Media and ZeroEyes, while facing securities class action litigation.
The stock presents high risk with substantial losses and negative cash flow from operations, though analyst consensus suggests potential upside to $3.75. Investment opportunity exists only for speculative investors betting on AI growth potential, with significant execution and litigation risks weighing on near-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
